袖状胃切除术会大幅增加胃食管反流病和糜烂性食管炎。
原始表述
ومع إن التكميم على عملية وحشة جدا ونتائجها وحشة جدا ومن أهم مضاعفاتها إنها بتزود ارتجاع المريء
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
袖状胃切除术会大幅增加胃食管反流病和糜烂性食管炎。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- عمليات السمنة ايه افضل عملية لصحتك وبدون خطورة (打开来源)
- 发布日期
- 2021年3月31日
- 时间戳
- 0:00:31 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); wording may contain transcription errors; no timestamps available. This 2021 transcript contains embedded time markers (approx. [00:29]); they come from the archive transcript, not from this project.
- 所声称的机制
Cutting the stomach into a tube raises intragastric pressure and changes the oesophagogastric junction.
- 所声称的健康影响
Chronic acid reflux, oesophagitis.
- 涉及人群
Sleeve gastrectomy patients
- Elawady 设定的地域限制
none found
来源版本存在差异
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (eltayebat.com); not necessarily Elawady's own words
- 出处
- https://eltayebat.com/rule/bariatric-surgery/
- 归属的不确定性
- Editorial summary/narrative and study selection written by the archive operators; the archive states that the cited research documents harm independently of Dr. Diaa's words.
科学评估
正确 – 该说法有可靠证据支持。
证据确定性: 高 – 进一步研究极不可能改变该评估。
1. 说法是什么？
That sleeve increases reflux.
2. 哪些内容可证实是正确的？
Correct: esophagitis 31% after sleeve vs 7% after bypass at 10 years (SLEEVEPASS); reflux worsened in 31.8% vs 6.3% (SM-BOSS); pooled RR for GERD symptoms 3.32 and PPI use 3.65 after sleeve (Chandan 2025).
3. 哪些内容是错误或夸大的？
Nothing substantial in this sub-claim.
4. 哪些内容仍不明确？
Long-term clinical consequences (cancer) remain uncertain. Severe (grade C/D) oesophagitis is uncommon (about 3%, I-BAR-111), and one RCT (Oseberg, I-BAR-116) found more pathological acid reflux but similar erosive oesophagitis after sleeve vs bypass at 5 years.
5. 哪些研究支持该说法？
A-BAR-07, A-BAR-08, A-BAR-09, I-BAR-04, I-BAR-05; new: SM-BOSS 10-year (I-BAR-142: more de novo GERD; conversions 29.9% vs 5.5%), meta-analyses I-BAR-109 (de novo reflux 23%, oesophagitis 28%) and I-BAR-112 (GERD 35%), Danish national data (I-BAR-144: GERD diagnosis HR 1.93 vs bypass), and the international consensus I-BAR-113 calling GERD the main drawback of sleeve.
6. 哪些研究与该说法相矛盾？
None identified for the direction of effect.
7. 对德国和欧洲而言情况如何？
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
8. 关于埃及的已知情况是什么？
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
9. 合理的实际结论是什么？
反流是袖状胃切除术有充分记录的常见缺点；存在明显反流时，通常首选胃旁路术。
评估详情
- 证据确定性的依据
Two RCTs (SLEEVEPASS, SM-BOSS) and a meta-analysis consistently show more reflux/oesophagitis after sleeve than after bypass or before surgery.
- 来源质量
Randomized trials plus meta-analysis.
- 地区可推广性
European RCTs; directly transferable.
- 个体例外情况
Some patients have less reflux after sleeve (SM-BOSS: 25% remission); pre-existing reflux and hiatal hernia increase risk.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
有充分科学证据支持 – 该说法与一致的高质量证据相符。
研究问题: Does sleeve gastrectomy increase gastro-oesophageal reflux disease and erosive oesophagitis compared with the preoperative state and with gastric bypass?
研究问题详解 (PICO)
- 人群
- Adults undergoing sleeve gastrectomy
- 干预或暴露
- Sleeve gastrectomy
- 对照
- Preoperative status; Roux-en-Y gastric bypass
- 地域范围
- universal biology (anatomical effect of the operation)
- 结局指标
- GERD symptoms/diagnosis
- Erosive oesophagitis
- PPI use
- Conversion for reflux
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Finnish trial: sleeve vs bypass after 10 years
SLEEVEPASS RCT: oesophagitis at 10 years far more frequent after sleeve than bypass.
- 实际结果
- Oesophagitis 31% vs 7% (P<.001).
- 方法学质量
- high (RCT)
- 相关性
- direct
- 局限
- Attrition; comparison with bypass, not with no surgery
Swiss trial: sleeve vs bypass after 10 years
SM-BOSS RCT >=10 y: more de novo GERD and many more conversions after sleeve.
- 实际结果
- Conversions 29.9% vs 5.5%; de novo GERD higher after SG (P=.02).
- 方法学质量
- high (RCT, 65% complete follow-up)
- 相关性
- direct
- 局限
- Attrition
Meta-analysis: Barrett's after sleeve
Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041 Meta分析已核查摘要Meta-analysis of long-term studies: GERD symptoms, oesophagitis and PPI use about three times more frequent after sleeve than before.
- 实际结果
- Erosive oesophagitis RR 3.37; GERD symptoms RR 3.32; PPI RR 3.65.
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Pre-post observational
哪些证据不支持该说法？
Norwegian trial: bypass vs sleeve in type 2 diabetes
Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6 随机对照试验已核查摘要新增Oseberg RCT: pathological acid reflux much more frequent after sleeve, but erosive oesophagitis prevalence similar to bypass at 5 years.
- 实际结果
- Pathological acid reflux RD 51.1% (28.0-74.2); erosive oesophagitis similar.
- 方法学质量
- high but small
- 相关性
- direct - limits only the oesophagitis part
- 局限
- n=109, secondary outcome
How often severe gullet inflammation follows sleeve
Severe (LA C/D) oesophagitis after sleeve is uncommon.
- 实际结果
- Pooled 3% (2-6%).
- 方法学质量
- moderate
- 相关性
- direct for severity
- 局限
- Observational
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Sleeve gastrectomy clearly increases reflux and acid-suppressant use and increases oesophagitis in most data; severe oesophagitis is uncommon.
为什么有些研究权重更大
Two European RCTs with >=10-y follow-up (SLEEVEPASS, SM-BOSS) and consistent meta-analyses weigh most; Oseberg adds nuance on oesophagitis severity.
因果关系是否已确立？ 是，已确立 Randomised comparisons and plausible mechanism (high intragastric pressure, altered angle of His, hiatal hernia).
仍存在的不确定性
Long-term consequences (Barrett, cancer); size of oesophagitis excess vs bypass differs between trials.
合理的结论
The claim is correct.
为什么研究结果看起来互相矛盾？
SLEEVEPASS found much more oesophagitis after sleeve, whereas Oseberg found similar oesophagitis but more pathological acid reflux; differences in follow-up (10 vs 5 y), endoscopy protocols, sample size and banded vs non-banded bypass likely explain this. Both confirm more reflux after sleeve.
这是否取决于国家？
- 一般生物学效应
- Anatomical effect; universal.
- 饮食习惯
- Not applicable (surgical procedure, not a food).
- 食品原产地
- Not applicable (surgical procedure, not a food).
- 污染物
- Not applicable (surgical procedure, not a food).
- 本国生产条件
- Surgical technique (hiatal hernia repair, sleeve shape) varies between centres.
- 法律规则
- Not applicable.
- 实际监测数据
- No Egyptian national bariatric registry data were found; one Egyptian single-surgeon series (I-BAR-105) and one Egyptian RCT (I-BAR-136) were identified.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Reproduce risk differences from counts – Diabetes remission RDs reproduced exactly (29.5%, 33.5%); reflux RD not recalculable (counts not in abstract). 已重新计算
- Detection bias between prospective and retrospective studies – Prospective 7% vs retrospective 2%: systematic endoscopy finds more severe oesophagitis; true value likely between. 无法根据已发表数据重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- GERD/oesophagitis after sleeve vs bypass or baseline
- 起始等级
- 高（随机试验）
- 降级理由
- none (minor attrition)
- 结果
- 高
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- International expert consensus (Montpellier): GERD and LSG: First International Consensus Conference (I-BAR-113) (2020) · 原始文献
GERD is probably the main drawback of LSG; endoscopy before (92%) and after (78%) surgery; higher-grade oesophagitis and Barrett are contraindications to LSG; RYGB recommended for uncontrolled GERD after sleeve. - IFSO: Position Statement on Upper GI Endoscopy Before and After MBS (I-BAR-114) (2025) · 原始文献
Barrett incidence after MBS estimated at 2.4% (very heterogeneous, high likelihood of bias, little follow-up beyond 2 years); seven recommendations on endoscopy before/after MBS (recommendation text not in abstract, not used). - ASMBS/IFSO: 2022 ASMBS and IFSO Indications for Metabolic and Bariatric Surgery (I-BAR-11) (2022) · 原始文献
Metabolic and bariatric surgery is recommended for BMI >35 regardless of comorbidities and should be considered for BMI 30-34.9 with metabolic disease; long-term results consistently demonstrate safety and efficacy (abstract; erratum noted in PubMed).
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | TITLE:"sleeve gastrectomy" AND (TITLE:"reflux" OR TITLE:"GERD" OR TITLE:"esophagitis" OR TITLE:"Barrett") AND (PUB_TYPE:"Meta-Analysis" OR TITLE:"meta-analysis") | 支持性证据 | 24 | |
| PubMed | 2026年10月26日 | (sleeve gastrectomy[ti]) AND (gastroesophageal reflux[tiab] OR GERD[tiab]) AND (de novo[tiab]) AND (systematic review[pt] OR meta-analysis[pt] OR randomized controlled trial[pt]) | 支持性证据 | 22 | |
| PubMed | 2026年10月26日 | (sleeve gastrectomy[ti]) AND (reflux[ti] OR GERD[ti]) AND (resolution[ti] OR remission[ti] OR improvement[ti] OR improves[ti] OR decrease*[ti]) | 反对性证据 | 21 | |
| Europe PMC | 2026年10月26日 | TITLE:"sleeve gastrectomy" AND (TITLE:"reflux" OR TITLE:"GERD") AND (TITLE:"improve*" OR TITLE:"resolution" OR TITLE:"remission" OR TITLE:"decrease*") AND PUB_YEAR:[2018 TO 2026] | 反对性证据 | 15 | |
| Europe PMC | 2026年10月26日 | (TITLE:"gastroesophageal reflux" OR TITLE:"GERD" OR TITLE:"reflux") AND (TITLE:"sleeve") AND (TITLE:"statement" OR TITLE:"consensus" OR TITLE:"guideline" OR TITLE:"position") | 指南 | 5 | |
| Europe PMC | 2026年10月26日 | AFF:"Egypt" AND TITLE:"sleeve gastrectomy" AND (TITLE:"reflux" OR TITLE:"GERD" OR TITLE:"esophagitis" OR TITLE:"Barrett") AND (TITLE:"randomized" OR TITLE:"randomised" OR TITLE:"prospective" OR TITLE:"long-term") | 双向 | 3 |
待解决的问题
Whether newer techniques (fundoplication-sleeve, hiatal repair) remove the excess.
核查深度如何？
12 项相关研究：0 项核查了全文（其中 0 项进行了结构化偏倚风险评估），12 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 正确 (高)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 正确 (高)
Verdict TRUE and certainty high unchanged; new 10-year SM-BOSS data and meta-analyses confirm it. Oseberg shows oesophagitis excess is not found in every trial, which is mentioned as nuance but does not change the verdict.
新来源: I-BAR-109 I-BAR-112 I-BAR-113 I-BAR-142 I-BAR-144 I-BAR-111 I-BAR-116
通俗解释
Elawady 说，袖状胃切除术会增加胃酸反流。这是正确的。在芬兰和瑞士的随机对照试验中，袖状胃切除术后反流和食管炎症的发生率比胃旁路术后高出数倍。许多袖状胃切除术患者需要服用抑酸药物。因此，对于已有反流的人，医生常常选择胃旁路术。
与该说法相关的研究
支持该说法的研究 (10)
-
Finnish trial: sleeve vs bypass after 10 years
Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究Esophagitis was found in 31% after sleeve vs 7% after bypass; Barrett's esophagus was 4% in both groups.
Sleeve gastrectomy substantially increases gastro-oesophageal reflux disease and erosive oesophagitis.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare sleeve vs bypass
- 研究是如何开展的？
RCT with 10-year follow-up
- 研究了多少人、动物或样本？
240 patients
- 实际发现了什么？
More esophagitis after sleeve; Barrett's equal
- 观察到的效应有多大？
31% vs 7%; BE 4% vs 4%
- 研究结果对日常生活意味着什么？
Sleeve often causes reflux damage; bypass less so
- 该研究有哪些局限？
Attrition; small
- 它对 Elawady 的具体说法说明了什么？
Supports reflux claim, not sleeve-specific Barrett's
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Cancer risk
-
Austrian follow-up 10+ years after sleeve
Felsenreich DM et al.. Obes Surg 2017 · PMID 28593484 · DOI 10.1007/s11695-017-2748-9病例系列 / 病例报告被 Tayebat 档案网站引用已核查摘要Many patients had reflux and 15% had Barrett's changes, but the study was very small.
Sleeve gastrectomy substantially increases gastro-oesophageal reflux disease and erosive oesophagitis.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Long-term reflux
- 研究是如何开展的？
Case series
- 研究了多少人、动物或样本？
43
- 实际发现了什么？
High BE rate
- 观察到的效应有多大？
15%
- 研究结果对日常生活意味着什么？
Signal of concern
- 该研究有哪些局限？
Small, early technique
- 它对 Elawady 的具体说法说明了什么？
Partly supports
- 研究结果是否适用于德国和欧洲？
European
- 从该研究中明确不能得出什么结论？
True incidence
-
Endoscopy 5+ years after sleeve
Sebastianelli L et al.. Obes Surg 2019 · PMID 30666544 · DOI 10.1007/s11695-019-03704-y横断面研究被 Tayebat 档案网站引用已核查摘要About 1 in 5 had Barrett's changes; reflux symptoms rose from 22% to 76%.
Sleeve gastrectomy substantially increases gastro-oesophageal reflux disease and erosive oesophagitis.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Prevalence
- 研究是如何开展的？
Cross-sectional
- 研究了多少人、动物或样本？
90
- 实际发现了什么？
High BE and GERD
- 观察到的效应有多大？
BE 18.8%
- 研究结果对日常生活意味着什么？
Reflux is frequent after sleeve
- 该研究有哪些局限？
Small, no control
- 它对 Elawady 的具体说法说明了什么？
Supports reflux claim
- 研究结果是否适用于德国和欧洲？
European
- 从该研究中明确不能得出什么结论？
Exact risk
-
Meta-analysis: Barrett's after sleeve
Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041Meta分析独立交叉核查已核查摘要★ 关键研究About 5.6% developed new Barrett's esophagus; reflux and acid-medication use were about 3 times more frequent after sleeve.
Sleeve gastrectomy substantially increases gastro-oesophageal reflux disease and erosive oesophagitis.
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
BE after SG
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
2046
- 实际发现了什么？
BE 5.6%; GERD x3
- 观察到的效应有多大？
RR GERD 3.32
- 研究结果对日常生活意味着什么？
Reflux is a major downside of sleeve
- 该研究有哪些局限？
Heterogeneous observational
- 它对 Elawady 的具体说法说明了什么？
Supports reflux/BE claim, not 'inevitable'
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Cancer risk
-
Swiss trial: sleeve vs bypass
Peterli R et al.. JAMA 2018 · PMID 29340679 · DOI 10.1001/jama.2017.20897随机对照试验独立交叉核查已核查摘要★ 关键研究Reflux got worse in about 32% after sleeve vs 6% after bypass.
Sleeve gastrectomy substantially increases gastro-oesophageal reflux disease and erosive oesophagitis.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare procedures
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
217
- 实际发现了什么？
More reflux after sleeve
- 观察到的效应有多大？
31.8% vs 6.3%
- 研究结果对日常生活意味着什么？
Reflux is common but not universal
- 该研究有哪些局限？
Exploratory reflux outcome
- 它对 Elawady 的具体说法说明了什么？
Supports increase, refutes 'inevitable'
- 研究结果是否适用于德国和欧洲？
European
- 从该研究中明确不能得出什么结论？
Long-term BE
-
Meta-analysis: reflux after sleeve
Yeung et al.. Ann Surg 2020 · PMID 30921053 · DOI 10.1097/SLA.0000000000003275Meta分析独立交叉核查已核查摘要★ 关键研究About 23 in 100 developed new reflux after sleeve, 28 in 100 had oesophagitis at long-term endoscopy, and 4 in 100 needed a second operation for reflux.
De novo reflux 23%, oesophagitis 28%.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Estimate reflux after sleeve
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
10,718 patients
- 实际发现了什么？
De novo reflux 23%; oesophagitis 28%; Barrett 8%
- 观察到的效应有多大？
Proportions
- 研究结果对日常生活意味着什么？
Reflux is a frequent downside, not universal
- 该研究有哪些局限？
Heterogeneous, uncontrolled
- 它对 Elawady 的具体说法说明了什么？
Supports "increases reflux"; contradicts "inevitable"
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Cancer risk
-
How often reflux disease develops after sleeve
Trujillo et al.. Obes Surg 2024 · PMID 38483740 · DOI 10.1007/s11695-024-07163-yMeta分析独立交叉核查已核查摘要About 1 in 3 patients developed reflux disease after sleeve (about 6 in 10 in trials with systematic testing).
Pooled GERD after LSG 35%.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Incidence of GERD after LSG
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
20,495
- 实际发现了什么？
35% overall
- 观察到的效应有多大？
Proportion 0.35
- 研究结果对日常生活意味着什么？
Reflux is common
- 该研究有哪些局限？
Very heterogeneous
- 它对 Elawady 的具体说法说明了什么？
Supports reflux claim; not "inevitable"
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Severity
-
International experts on reflux and sleeve
Assalia et al.. Obes Surg 2020 · PMID 32533520 · DOI 10.1007/s11695-020-04749-0指南 / 立场声明独立交叉核查已核查摘要Experts agreed that reflux is probably the main drawback of sleeve and that bypass is preferable when severe reflux exists.
Experts call GERD the main drawback of LSG.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Agree on GERD management
- 研究是如何开展的？
Expert consensus
- 研究了多少人、动物或样本？
46 experts
- 实际发现了什么？
Endoscopy before/after; bypass for severe GERD
- 观察到的效应有多大？
Agreement %
- 研究结果对日常生活意味着什么？
Doctors take reflux after sleeve seriously
- 该研究有哪些局限？
Opinion-based
- 它对 Elawady 的具体说法说明了什么？
Supports reflux concern
- 研究结果是否适用于德国和欧洲？
International
- 从该研究中明确不能得出什么结论？
Does not condemn sleeve generally
-
Swiss trial: sleeve vs bypass after 10 years
Kraljevic et al.. JAMA Surg 2025 · PMID 39969869 · DOI 10.1001/jamasurg.2024.7052随机对照试验独立交叉核查已核查摘要★ 关键研究After more than 10 years, 3 in 10 sleeve patients needed a conversion operation (for reflux or weight) vs about 1 in 20 after bypass; new reflux was more common after sleeve.
More de novo GERD after SG at >=10 y (RCT).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare long-term SG and RYGB
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
217
- 实际发现了什么？
More conversions and de novo GERD after SG
- 观察到的效应有多大？
29.9% vs 5.5% conversions
- 研究结果对日常生活意味着什么？
Sleeve has more long-term reflux problems
- 该研究有哪些局限？
Attrition
- 它对 Elawady 的具体说法说明了什么？
Supports reflux and bypass-preference parts
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Mortality differences
-
Danish study: acid medicines after sleeve vs bypass
Gormsen et al.. Int J Obes (Lond) 2024 · PMID 39043831 · DOI 10.1038/s41366-024-01593-5队列研究独立交叉核查已核查摘要Sleeve patients were much more likely to start acid-reducing medicines and to keep taking them than bypass patients.
GERD diagnosis HR 1.93 vs RYGB.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
PPI use after SG vs RYGB
- 研究是如何开展的？
National cohort
- 研究了多少人、动物或样本？
17,740
- 实际发现了什么？
More PPI use after SG
- 观察到的效应有多大？
HR 7.06
- 研究结果对日常生活意味着什么？
Many sleeve patients need acid medicines
- 该研究有哪些局限？
Small SG group
- 它对 Elawady 的具体说法说明了什么？
Partly supports
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Lifelong need for all
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (0)
该组中没有研究。
结果不一或不明确的研究 (2)
-
How often severe gullet inflammation follows sleeve
Alqasem et al.. Obes Surg 2026 · PMID 41964778 · DOI 10.1007/s11695-026-08605-5Meta分析独立交叉核查已核查摘要About 3 in 100 sleeve patients had severe inflammation of the gullet at endoscopy.
Confirms GERD frequent; severe EE uncommon.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Severe oesophagitis after SG
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
1,587
- 实际发现了什么？
3% (7% in prospective studies)
- 观察到的效应有多大？
Proportion
- 研究结果对日常生活意味着什么？
Severe damage is uncommon
- 该研究有哪些局限？
Small, observational
- 它对 Elawady 的具体说法说明了什么？
Limits "inevitable" framing
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Cancer risk
-
Norwegian trial: bypass vs sleeve in type 2 diabetes
Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6随机对照试验独立交叉核查已核查摘要★ 关键研究After 5 years, diabetes was in remission in 50% after bypass vs 20% after sleeve; acid reflux was more common after sleeve, but Barrett changes were similar.
Pathological acid reflux more after SG; erosive oesophagitis similar to bypass.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare RYGB and SG in T2D
- 研究是如何开展的？
Randomised trial
- 研究了多少人、动物或样本？
109
- 实际发现了什么？
Bypass better for remission and weight; sleeve more acid reflux
- 观察到的效应有多大？
RD 29.5%
- 研究结果对日常生活意味着什么？
Bypass helps diabetes more but is not a cure
- 该研究有哪些局限？
Small, single centre
- 它对 Elawady 的具体说法说明了什么？
Supports bypass preference for diabetes/reflux; contradicts "complete cure"
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Long-term hard outcomes
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
埃及
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
在我的国家适用什么？
一般科学评估
正确 正确：袖状胃切除术明显增加反流和食管炎。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial.. Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229
- Reflux, Sleeve Dilation, and Barrett's Esophagus after Laparoscopic Sleeve Gastrectomy: Long-Term Follow-Up.. Felsenreich DM et al.. Obes Surg 2017 · PMID 28593484 · DOI 10.1007/s11695-017-2748-9
- Systematic Endoscopy 5 Years After Sleeve Gastrectomy Results in a High Rate of Barrett's Esophagus: Results of a Multicenter Study.. Sebastianelli L et al.. Obes Surg 2019 · PMID 30666544 · DOI 10.1007/s11695-019-03704-y
- Risk of De Novo Barrett's Esophagus Post Sleeve Gastrectomy: A Systematic Review and Meta-Analysis of Studies With Long-Term Follow-Up.. Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041
- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial.. Peterli R et al.. JAMA 2018 · PMID 29340679 · DOI 10.1001/jama.2017.20897
- Does Sleeve Gastrectomy Expose the Distal Esophagus to Severe Reflux?: A Systematic Review and Meta-analysis.. Yeung et al.. Ann Surg 2020 · PMID 30921053 · DOI 10.1097/SLA.0000000000003275
- Incidence of Post-operative Gastro-esophageal Reflux Disorder in Patients Undergoing Laparoscopic Sleeve Gastrectomy: A Systematic Review and Meta-analysis.. Trujillo et al.. Obes Surg 2024 · PMID 38483740 · DOI 10.1007/s11695-024-07163-y
- Gastroesophageal Reflux and Laparoscopic Sleeve Gastrectomy: Results of the First International Consensus Conference.. Assalia et al.. Obes Surg 2020 · PMID 32533520 · DOI 10.1007/s11695-020-04749-0
- Long-Term Outcomes of Laparoscopic Roux-en-Y Gastric Bypass vs Laparoscopic Sleeve Gastrectomy for Obesity: The SM-BOSS Randomized Clinical Trial.. Kraljevic et al.. JAMA Surg 2025 · PMID 39969869 · DOI 10.1001/jamasurg.2024.7052
- Use of proton pump inhibitors after laparoscopic gastric bypass and sleeve gastrectomy: a nationwide register-based cohort study.. Gormsen et al.. Int J Obes (Lond) 2024 · PMID 39043831 · DOI 10.1038/s41366-024-01593-5
- Prevalence of Severe Erosive Esophagitis After Sleeve Gastrectomy: A Systematic Review and Meta-Analysis.. Alqasem et al.. Obes Surg 2026 · PMID 41964778 · DOI 10.1007/s11695-026-08605-5
- Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.. Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6